WSMOS Spring 2018 Oncology Conference

8:00am - 6:00pm

All Practicing Physicians/NPs/PAs and their supporting staff are welcome to attend at no cost.

Register Here: Register

If you are Industry employed please contact Liz Cleland wsmos@comcast.net as attendance invitations are given based on corporate membership levels.

Click Here: Agenda  


The WSMOS Spring Conference agenda is set and is packed with the most up-to-date topics and information. Clinical sessions include presentations on A phase I trial of 90Y-BC8-DOTA (anti-CD45) monoclonal antibody in combination with Fludarabine and TBI as conditioning for allogenic peripheral blood stem cell transplant to treat high-risk multiple myeloma, transplant associated thrombotic microangiopathy (TA-TMA), CAR T cell therapy in multiple myeloma, a “practical” guide to the management of the penta-refractory myeloma patient and a first-hand account by Dr. Tony Blau on a cancer patient’s war on cancer. Other sessions include a study on racial disparities in end-of-life care planning and hospital utilization, an update on ASCO’s State Affiliate Counsel and community initiatives and a Medicare update with Noridian CMD, Dick Whitten.

A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Sherilyn A. Tuazon, MD, Univ. of WA/Fred Hutchinson Cancer Research Center